Nature Cancer, Published online: 01 October 2025; doi:10.1038/s43018-025-01044-8

Investment continues as the field awaits phase 3 readouts for next-generation radioligand therapies in 2026.

Nature Biotechnology, Published online: 13 December 2024; doi:10.1038/s41587-024-02506-7

Merger and acquisition activity is at a seven-year low in 2024 as buyers digest prior deals and US election jitters delayed further spending. Expect a pick-up in 2025.

Nature Biotechnology, Published online: 12 June 2024; doi:10.1038/s41587-024-02295-z

Targeted radiopharmaceuticals offer resistance-free potency, pre-treatment imaging and widespread combination potential. Big pharma and investors are piling in.